VA
MRNA icon

Vident Advisory’s Moderna MRNA Stock Holding History

Vident Advisory’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$463K Sell
6,613
-1,175
-15% -$60.8K ﹤0.01% 1408
2026
Q1 		$396K Buy
+7,788
New +$363K ﹤0.01% 1368
2025
Q3 		– Sell
-7,468
Closed -$206K – 1705
2025
Q2 		$206K Buy
+7,468
New +$197K ﹤0.01% 1491
2024
Q4 		– Sell
-8,438
Closed -$564K – 1511
2024
Q3 		$564K Buy
+8,438
New +$775K 0.01% 863

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Vident Advisory's MRNA Position: Q2 2026 in Review

Vident Advisory reduced its Moderna (MRNA) stake by 15% in Q2 2026, selling an estimated $60.8K and leaving 6,613 shares worth $463K. The position accounts for ﹤0.01% of the portfolio, ranked #1408.

Vident Advisory first reported a position in MRNA in Q3 2024 and has held it in 4 quarters since. The position peaked at $564K in Q3 2024. 777 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Vident Advisory held 6,613 shares of Moderna worth $463K as of Q2 2026.
  • Vident Advisory sold 1,175 Moderna shares in Q2 2026, an estimated $60.8K.
  • Moderna made up ﹤0.01% of Vident Advisory's portfolio in Q2 2026, its #1408 holding.
  • Vident Advisory first reported a position in Moderna in Q3 2024 and has held it in 4 quarters since.
  • Vident Advisory's Moderna position peaked at $564K in Q3 2024.
  • 777 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Vident Advisory's 13F filing for Q2 2026, filed 12 Aug 2026.